Clinical Trial: Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial

Brief Summary: This Study is single arm, single centre trial to check the safety and efficacy of Bone Marrow derived autologous cell(100 million per dose) for the patient with Duchenne Muscular Dystrophy.

Detailed Summary: Muscular dystrophy is a group of inherited disorders that involve muscle weakness and loss of muscle tissue, which get worse over time. Duchenne muscular dystrophy is caused by a defective gene for dystrophin (a protein in the muscles). However, it often occurs in people without a known family history of the condition. slowly progress diseases.it causes Muscle weaknesses, Difficulty with motor skills ,Progressive difficulty walking.Breathing difficulties and heart disease,Frequent falls,weak limbs,lose motor Function.Begins in the legs and pelvis, but also occurs less severely in the arms, neck, and other areas of the body.Trouble getting up from a lying position or climbing stairs.
Sponsor: Chaitanya Hospital, Pune

Current Primary Outcome: Significant Improvement in Muscle strength by using Kinetics Muscle testing or by using MMT( manual muscle test }score [ Time Frame: 6 Months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: -Improvement of daily living scale and baseline in EMG(electromyography) [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: Chaitanya Hospital, Pune

Dates:
Date Received: February 26, 2013
Date Started: September 2014
Date Completion: December 2016
Last Updated: September 16, 2014
Last Verified: September 2014